Integra LifeSciences Holdings (IART) shares were up past 21% in early trading on Tuesday after the company reported Q1 adjusted earnings and revenue that rose year on year and beat analysts' estimates.
The company reported Q1 adjusted earnings of $0.54 per diluted share, up from $0.41 a year earlier. Analysts polled by FactSet expected $0.40.
Revenue for the quarter ended March 31 was $391.9 million, up from $382.7 million a year earlier. Analysts surveyed by FactSet expected $381.8 million.
For Q2, the company expects adjusted EPS of $0.44 to $0.52 and revenue of $410 million to $425 million. Analysts polled by FactSet expect $0.53 and $427.5 million.
For 2026, the company now expects adjusted EPS of $2.40 to $2.50, up from $2.30 and $2.40 previously, and it reiterated the revenue outlook of $1.662 billion to $1.702 billion. Analysts surveyed by FactSet expect $2.34 and $1.67 billion, respectively.
Separately, the company said Tuesday that Chairman Stuart Essig has been named president and chief executive officer. Essig will continue to serve as chair, Integra said, adding that he succeeds Mojdeh Poul, who is pursuing other opportunities.
Additionally, Michael McBreen, currently executive vice president, president, Codman Specialty Surgical, has been named chief commercial officer, Integra said.
Price: $13.10, Change: $+2.45, Percent Change: +23.00%